Caladrius Takes Former Baxalta Angina Program Off Shire's Hands
Shire has divested a cell therapy program for angina it picked up via the acquisition of Baxalta in 2016; Caladrius hopes to bring the Phase III treatment to the US market soon.
Shire has divested a cell therapy program for angina it picked up via the acquisition of Baxalta in 2016; Caladrius hopes to bring the Phase III treatment to the US market soon.